Genomics is a comprehensive study of the whole genome, genetic products, and their interactions. Human genome project has identified around 25,000-30,000 genes, and prevailing presence in tumor pathogenesis, high number of mutations, epigenetic changes, and other gene disorders have been identified. Microarrays technology is used for the analysis of these changes. Postgenome age has begun, and the initial results ensure the improvement of molecular tumor diagnostics and the making of a new taxonomic tumor classification, as well as the improvement, optimization and individualization of anti-tumor therapy. First genomic classifications have been made of leukemias, non-Hodgkin lymphoma, and many solid tumors. For example, 4 molecular types of breast carcinoma, three types of diffuse B cell lymphoma, two types of chromophobic renal carcinoma have been identified. Also, gene structures for favorable and unfavorable outcome in leukemia, breast cancer, prostate, bronchi, and other tumors have been identified. It is absolutely possible to diagnose the primary outcome of tumors with which standard tumor position may not be proved using standard diagnostic tools. Pharmacogenomic profiles have ensured better definition of interindividual differences during therapy using antineoplastic drugs and the decrease of their toxicity, as well as individual treatment approach and patient selection with which favorable clinical outcome is expected. Pharmacogenomics has impacted the accelerated development of target drugs, which have showed to be useful in practice. New genomic markers mtDNA, meDNA, and miRNA have been identified, which, with great certainty, help the detection and diagnostics of carcinoma. In the future, functional genomics in clinical oncology provides to gain knowledge about tumor pathogenesis; it will improve diagnostics and prognosis, and open up new therapeutic options.
65. Monecke S, Muller E, Dorneanu OS, Vremeră T, Ehricht R. MolecularTyping of MRSA and of Clinical Staphylococcus aureus Isolates from Iasi, Romania. PLoS ONE. 2014 May;9(5):e97833. DOI: 10.1371/journal.pone.0097833 66. Scheithauer S, Trepels-Kottek S, Häfner H, Keller D, Ittel T, Wagner N, et al. Healthcare worker-related MRSA cluster in a German neonatology level III ICU: A true European story. Int J Hyg Environ Health. 2014 Mar;217(2-3):307-11. DOI: 10.1016/j.ijheh.2013.07.006 67. Pammi M, Davis RJ, Gordon A, Starke J. Infant isolation and cohorting for
, Niculcea A, Popescu GA, et al. The use of PCR Ribotyping for moleculartyping of clinically significant Clostridium difficile Romanian isolates. Rom Biotechnol Lett.2017;22(5). 29. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 7.1. 2017; http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_7.1_Breakpoint. 30. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. CLSI document M100-27th ed. 2017